Literature DB >> 25716337

Recent Advances in the Diagnosis and Management of Bladder Cancer.

Xiaoying Zhang1, Conghui Han2, Jantai He3.   

Abstract

The most common malignancy of urinary tract is bladder cancer. It is one of the most widespread cancers of the world and ranks nine among frequent malignancies existing in world. The only solution to above burning problem is timely diagnosis at earlier stage, and the cancer research is being forwarded in this direction. There are various prominent gene modifications responsible for growth of bladder cancer. The present review is focused on recent advances in the field of cancer makers involving, genetic, urinary, pathological, etc., approaches to contain the deadly process of carcinogenesis. The present review provides an insight on the emerging biomarkers that could be developed to boost current bladder cancer detection strategies. This shall help timely diagnosis of this deadly disease at early stage, thereby, helping bladder cancer patients to fight against this iniquity of life.

Entities:  

Keywords:  Bladder cancer; Genes; Genetic modulations

Mesh:

Substances:

Year:  2015        PMID: 25716337     DOI: 10.1007/s12013-015-0632-6

Source DB:  PubMed          Journal:  Cell Biochem Biophys        ISSN: 1085-9195            Impact factor:   2.194


  8 in total

1.  GSG2 (Haspin) promotes development and progression of bladder cancer through targeting KIF15 (Kinase-12).

Authors:  Yuhao Chen; Dian Fu; Hai Zhao; Wen Cheng; Feng Xu
Journal:  Aging (Albany NY)       Date:  2020-05-21       Impact factor: 5.682

2.  BET inhibitor JQ1 suppresses cell proliferation via inducing autophagy and activating LKB1/AMPK in bladder cancer cells.

Authors:  Feng Li; Chao Yang; Hai-Bao Zhang; Jianbin Ma; Jing Jia; Xiaoshuang Tang; Jin Zeng; Tie Chong; Xinyang Wang; Dalin He; Peng Guo
Journal:  Cancer Med       Date:  2019-06-28       Impact factor: 4.452

3.  lncRNA MIR4435-2HG Accelerates the Development of Bladder Cancer through Enhancing IQGAP3 and CDCA5 Expression.

Authors:  Tao Yang; Yan Li; Gang Wang; Liuxiong Guo; Fuzhen Sun; Shoubin Li; Xinna Deng; Junjiang Liu
Journal:  Biomed Res Int       Date:  2022-08-12       Impact factor: 3.246

4.  Lidocaine enhances the effects of chemotherapeutic drugs against bladder cancer.

Authors:  Xihua Yang; Lili Zhao; Meiping Li; Lei Yan; Shengwan Zhang; Zhenguo Mi; Liansheng Ren; Jun Xu
Journal:  Sci Rep       Date:  2018-01-12       Impact factor: 4.379

5.  Protosappanin B promotes apoptosis and causes G1 cell cycle arrest in human bladder cancer cells.

Authors:  Xihua Yang; Lili Zhao; Tingting Zhang; Junfeng Xi; Shuze Liu; Liansheng Ren; Yaqin Zheng; Huanhu Zhang
Journal:  Sci Rep       Date:  2019-01-31       Impact factor: 4.379

Review 6.  Hydrogen Sulfide: Emerging Role in Bladder, Kidney, and Prostate Malignancies.

Authors:  Masoud Akbari; Emrullah Sogutdelen; Smriti Juriasingani; Alp Sener
Journal:  Oxid Med Cell Longev       Date:  2019-11-03       Impact factor: 6.543

7.  CircPTPRA acts as a tumor suppressor in bladder cancer by sponging miR-636 and upregulating KLF9.

Authors:  Qingqing He; Lifang Huang; Dong Yan; Junming Bi; Meihua Yang; Jian Huang; Tianxin Lin
Journal:  Aging (Albany NY)       Date:  2019-12-10       Impact factor: 5.682

8.  DEPDC1B is a tumor promotor in development of bladder cancer through targeting SHC1.

Authors:  Chin-Hui Lai; Kexin Xu; Jianhua Zhou; Mingrui Wang; Weiyu Zhang; Xianhui Liu; Jie Xiong; Tao Wang; Qi Wang; Huanrui Wang; Tao Xu; Hao Hu
Journal:  Cell Death Dis       Date:  2020-11-17       Impact factor: 8.469

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.